Session » Immunological Complications of Therapy Poster

Date: Monday, November 9, 2020

Time: 9:00AM-11:00AM

Meeting: ACR Convergence 2020

9:00AM-11:00AM: Abstract Number: 1576

Acute Respiratory Viral Adverse Events During Use of Antirheumatic Disease Therapies: A Scoping Review

9:00AM-11:00AM: Abstract Number: 1579

Assessing the Effect of Calcineurin Inhibitors for Immune-related Adverse Event Management on Tumor Response

9:00AM-11:00AM: Abstract Number: 1567

Association of Blood Count Biomarkers and Clinical Features with Immune Related Adverse Events (irAEs) in Patients with Cancer Treated with Checkpoint Inhibitors (CPI)

9:00AM-11:00AM: Abstract Number: 1575

CD6 Is a Target for Cancer Immunotherapy

9:00AM-11:00AM: Abstract Number: 1572

Clinical Characteristics of Methotrexate Associated Lymphoproliferative Disorders and RA Treatment After Lymphoproliferative Onset in 92 Cases

9:00AM-11:00AM: Abstract Number: 1571

Distinct T Cell Responses in Inflammatory Arthritis Associated with Combined CTLA-4 and PD-1 Inhibitor Therapy

9:00AM-11:00AM: Abstract Number: 1580

Generalized Immune Activation in Structures Related to PMR or GCA on PET/CT Assessment Does Not Occur in Immune Checkpoint Inhibitor-Treated Patients Who Do Not Go on to Develop Rheumatic Immune-Related Adverse Events

9:00AM-11:00AM: Abstract Number: 1573

Gout as an Immune-Related Adverse Event from Immune Checkpoint Inhibitors

9:00AM-11:00AM: Abstract Number: 1570

Immune Checkpoint Inhibitor Treatment in Cancer: Immunomodulator Use and Evaluation by Rheumatology

9:00AM-11:00AM: Abstract Number: 1577

Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis Impact on Function and Patient-Reported Quality of Life Measures Varies Depending on Pattern of Arthritis

9:00AM-11:00AM: Abstract Number: 1569

Immune Related Adverse Events Related to Check Point Inhibitors Among Outpatients in an Academic Center

9:00AM-11:00AM: Abstract Number: 1568

Impact of the SARS-CoV-2 Pandemic on a Cohort of Patients with Rheumatic Complications of Immune Checkpoint Inhibitors: A Registry Survey Study

9:00AM-11:00AM: Abstract Number: 1581

Neutrophil to Lymphocyte Ratio as a Predictor of Immune-Related Adverse Events in CTLA-4 Treated Patients: A Retrospective Review

9:00AM-11:00AM: Abstract Number: 1566

Onset and Disease Course of Inflammatory Arthritis in Patients Receiving Immune Checkpoint Inhibitor Therapy at a Single Institution

9:00AM-11:00AM: Abstract Number: 1574

Over Half of Patients with Immune Checkpoint Inhibitor-related Myositis, Myasthenia Gravis and/or Myocarditis Have Autoantibodies: Results from a Systematic Literature Review

9:00AM-11:00AM: Abstract Number: 1578

Rituximab Hypersensitivity in Rheumatic and Inflammatory Diseases: Role of Skin Testing

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].